{"transactions":[{"id":801309,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":2,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":3,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2026-04-24T22:16:02.000Z","date":"2026-04-17","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":2,"value":200000.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II\"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II\"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF II under Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":572942,"source":{"system":"sec-edgar","filing":"0001213900-26-047650","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/919484/000121390026047650/ownership.xml","form_type":"4"}},{"id":869669,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-03-03T21:06:40.000Z","date":"2026-02-27","kind":"purchase","planned":false,"acquired":true,"shares":1543,"price":9.72,"value":14997.96,"ownership":{"direct":false,"nature":"HEP Investment, LLC"},"balance_after":583615,"source":{"system":"sec-edgar","filing":"0001654954-26-001833","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495426001833/section16.xml","form_type":"4"}},{"id":902152,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":2,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":3,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock Purchase Warrant","published_at":"2026-02-17T11:22:38.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II\"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II\"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF II under Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":45071,"derivative":{"exercise_price":9.77,"exercise_date":"2026-02-12","expiration_date":"2031-02-11","underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001213900-26-016803","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/919484/000121390026016803/ownership.xml","form_type":"4"}},{"id":902151,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":2,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":3,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2026-02-17T11:22:38.000Z","date":"2026-02-12","kind":"purchase","planned":false,"acquired":true,"shares":20000,"price":9.77,"value":195400.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II\"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II\"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF II under Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":472942,"source":{"system":"sec-edgar","filing":"0001213900-26-016803","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/919484/000121390026016803/ownership.xml","form_type":"4"}},{"id":908097,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-02-12T14:21:50.000Z","date":"2026-02-10","kind":"purchase","planned":false,"acquired":true,"shares":2434,"price":10.27,"value":24997.18,"ownership":{"direct":false,"nature":"HEP Investments LLC"},"balance_after":582072,"source":{"system":"sec-edgar","filing":"0001654954-26-001157","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495426001157/section16.xml","form_type":"4"}},{"id":929178,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2026-01-28T21:11:45.000Z","date":"2026-01-26","kind":"purchase","planned":false,"acquired":true,"shares":11709,"price":8.54,"value":99994.86,"ownership":{"direct":true},"balance_after":279481,"source":{"system":"sec-edgar","filing":"0001654954-26-000652","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495426000652/section16.xml","form_type":"4"}},{"id":929177,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68620,"kind":"person","name":"PAYNE JOHN BERNARD","position":1,"cik":"0001582392","reported_name":"PAYNE JOHN BERNARD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-01-28T21:06:16.000Z","date":"2026-01-26","kind":"purchase","planned":false,"acquired":true,"shares":11709,"price":8.54,"value":99994.86,"ownership":{"direct":true},"balance_after":19618,"source":{"system":"sec-edgar","filing":"0001654954-26-000651","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495426000651/section16.xml","form_type":"4"}},{"id":930276,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-27T22:09:32.000Z","date":"2026-01-14","kind":"purchase","planned":false,"acquired":true,"shares":1766,"price":8.49,"value":14993.34,"ownership":{"direct":true},"balance_after":519292,"source":{"system":"sec-edgar","filing":"0001654954-26-000631","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495426000631/section16.xml","form_type":"4"}},{"id":930275,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2026-01-27T22:09:23.000Z","date":"2026-01-14","kind":"purchase","planned":false,"acquired":true,"shares":1766,"price":8.49,"value":14993.34,"ownership":{"direct":false,"nature":"by HEP Investments LLC"},"balance_after":579638,"source":{"system":"sec-edgar","filing":"0001654954-26-000630","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495426000630/section16.xml","form_type":"4"}},{"id":984048,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-12-02T23:43:14.000Z","date":"2025-11-28","kind":"purchase","planned":false,"acquired":true,"shares":2777,"price":9,"value":24993.0,"ownership":{"direct":false,"nature":"by  HEP Investments LLC"},"balance_after":577872,"source":{"system":"sec-edgar","filing":"0001641073-25-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000164107325000004/primary_doc.xml","form_type":"4"}},{"id":1016024,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":2,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":3,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock Purchase Warrant","published_at":"2025-10-20T20:19:13.000Z","date":"2025-10-13","kind":"purchase","planned":false,"acquired":true,"shares":2025,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II\"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF II under Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":43071,"derivative":{"exercise_price":12.34,"exercise_date":"2025-10-13","expiration_date":"2030-10-12","underlying":"Common Stock","underlying_shares":2025},"source":{"system":"sec-edgar","filing":"0001213900-25-100376","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/919484/000121390025100376/ownership.xml","form_type":"4"}},{"id":1016023,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":2,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":3,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2025-10-20T20:19:13.000Z","date":"2025-10-13","kind":"purchase","planned":false,"acquired":true,"shares":20259,"price":12.34,"value":249996.06,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II\"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II\"), which were acquired pursuant to a Securities Purchase Agreement that SMF II entered into with the issuer."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF II under Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":452942,"source":{"system":"sec-edgar","filing":"0001213900-25-100376","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/919484/000121390025100376/ownership.xml","form_type":"4"}},{"id":1019561,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-10-14T22:10:23.000Z","date":"2025-10-10","kind":"purchase","planned":false,"acquired":true,"shares":1659,"price":12.05,"value":19990.95,"ownership":{"direct":false,"nature":"by HEP Investments LLC"},"balance_after":575095,"source":{"system":"sec-edgar","filing":"0001654954-25-011774","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425011774/section16.xml","form_type":"4"}},{"id":1020997,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-09T20:28:24.000Z","date":"2025-10-08","kind":"purchase","planned":false,"acquired":true,"shares":23682,"price":12.01,"value":284420.82,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Due to an administrative error, the amount previously reported in this Item 5 overstated the aggregate beneficial ownership of the reporting person by 13,156 shares of Common Stock. The number stated in Item 5 to this Form 4 has been updated to correct the reporting person's aggregate beneficial ownership."}],"balance_after":517526,"source":{"system":"sec-edgar","filing":"0001654954-25-011614","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425011614/section16.xml","form_type":"4"}},{"id":1023602,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Nonstatutory Stock Options to buy Common Stock","published_at":"2025-10-07T00:36:14.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":926,"price":10.2,"value":9445.2,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was issued to the reporting person pursuant to the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $9,452.05."}],"balance_after":926,"derivative":{"exercise_price":12.03,"exercise_date":"2025-10-02","expiration_date":"2035-10-02","underlying":"Common Stock","underlying_shares":926},"source":{"system":"sec-edgar","filing":"0001654954-25-011515","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425011515/section16.xml","form_type":"4"}},{"id":1023601,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Nonstatutory Stock Options to buy Common Stock","published_at":"2025-10-07T00:30:19.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":1075,"price":10.2,"value":10965.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was issued to the reporting person pursuant to the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $10,964.38"}],"balance_after":1075,"derivative":{"exercise_price":12.03,"exercise_date":"2025-10-02","expiration_date":"2035-10-02","underlying":"Common Stock","underlying_shares":1075},"source":{"system":"sec-edgar","filing":"0001654954-25-011513","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425011513/section16.xml","form_type":"4"}},{"id":1023600,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Nonstatutory Stock Options to buy Common Stock","published_at":"2025-10-07T00:23:38.000Z","date":"2025-10-02","kind":"grant","planned":false,"acquired":true,"shares":1223,"price":10.2,"value":12474.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This option was issued to the reporting person pursuant to the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $12,476.71."}],"balance_after":1223,"derivative":{"exercise_price":12.03,"exercise_date":"2025-10-02","expiration_date":"2035-10-02","underlying":"Common Stock","underlying_shares":1223},"source":{"system":"sec-edgar","filing":"0001654954-25-011510","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425011510/section16.xml","form_type":"4"}},{"id":1027868,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-10-03T01:19:43.000Z","date":"2025-09-30","kind":"purchase","planned":false,"acquired":true,"shares":15322,"price":15.99,"value":244998.78,"ownership":{"direct":false,"nature":"by HEP Investments LLC"},"balance_after":573436,"source":{"system":"sec-edgar","filing":"0001641073-25-000003","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000164107325000003/primary_doc.xml","form_type":"4"}},{"id":1110234,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Warrant for Common Stock","published_at":"2025-06-16T21:04:19.000Z","date":"2025-06-13","kind":"purchase","planned":false,"acquired":true,"shares":348,"price":14.33,"value":4986.84,"ownership":{"direct":false,"nature":"By HEP Investments LLC"},"balance_after":348,"derivative":{"exercise_price":14.33,"exercise_date":"2025-06-13","expiration_date":"2030-06-13","underlying":"Common Stock","underlying_shares":348},"source":{"system":"sec-edgar","filing":"0001654954-25-007028","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425007028/section16.xml","form_type":"4"}},{"id":1110233,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-06-16T21:04:19.000Z","date":"2025-06-13","kind":"purchase","planned":false,"acquired":true,"shares":3488,"price":14.33,"value":49983.04,"ownership":{"direct":false,"nature":"By HEP Investments LLC"},"balance_after":558114,"source":{"system":"sec-edgar","filing":"0001654954-25-007028","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425007028/section16.xml","form_type":"4"}},{"id":1174876,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2025-04-10T01:42:34.000Z","date":"2025-04-08","kind":"sale","planned":false,"acquired":false,"shares":20,"price":16.25,"value":325.0,"ownership":{"direct":true},"balance_after":507000,"source":{"system":"sec-edgar","filing":"0001654954-25-004085","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425004085/section16.xml","form_type":"4"}},{"id":1177876,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-04-04T12:23:32.000Z","date":"2025-01-22","kind":"purchase","planned":false,"acquired":true,"shares":2880,"price":17.528,"value":50480.64,"ownership":{"direct":false,"nature":"By HEP Investments LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were acquired in exchange for the release of certain obligations of the Company under the License Co-Development Participation Agreement."}],"balance_after":554626,"source":{"system":"sec-edgar","filing":"0001654954-25-003907","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425003907/section16.xml","form_type":"4"}},{"id":1177875,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-04-04T12:23:32.000Z","date":"2025-01-22","kind":"purchase","planned":false,"acquired":true,"shares":7200,"price":17.528,"value":126201.6,"ownership":{"direct":false,"nature":"By HEP Investments LLC"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The shares were acquired in exchange for the release of certain obligations of the Company under the License Co-Development Participation Agreement."}],"balance_after":551746,"source":{"system":"sec-edgar","filing":"0001654954-25-003907","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425003907/section16.xml","form_type":"4"}},{"id":1296911,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":2,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":3,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock Purchase Warrant","published_at":"2025-01-24T00:48:25.000Z","date":"2024-08-27","kind":"purchase","planned":false,"acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF under Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":44171,"derivative":{"exercise_price":8.44,"exercise_date":"2024-08-27","expiration_date":"2029-08-27","underlying":"Common Stock"},"source":{"system":"sec-edgar","filing":"0001213900-25-006114","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/919484/000121390025006114/ownership.xml","form_type":"5"}},{"id":1296910,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":2,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":3,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2025-01-24T00:48:25.000Z","date":"2024-08-27","kind":"purchase","planned":false,"acquired":true,"shares":30000,"price":8.44,"value":253200.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund II, LP (\"SMF II)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF under Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":398683,"source":{"system":"sec-edgar","filing":"0001213900-25-006114","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/919484/000121390025006114/ownership.xml","form_type":"5"}},{"id":1299129,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":2,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":3,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"Affiliate of 10% Owner"}}],"security":"Common Stock","published_at":"2025-01-21T13:00:23.000Z","date":"2025-01-17","kind":"other","planned":false,"acquired":true,"shares":34000,"price":18.5,"value":629000.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund, LP (\"SMF\"). On January 17, 2025, SMF entered into an Exchange Agreement with the Issuer, pursuant to which in exchange for cancelling the License Co-Development Participation Agreement between the Issuer and SMF dated October 8, 2020, the Issuer agreed to issue to SMF the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are owned directly by Strome Mezzanine Fund, LP (\"SMF\"). On January 17, 2025, SMF entered into an Exchange Agreement with the Issuer, pursuant to which in exchange for cancelling the License Co-Development Participation Agreement between the Issuer and SMF dated October 8, 2020, the Issuer agreed to issue to SMF the reported securities."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Strome Investment Management, LP is the general partner of SMF. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for and to beneficially own the shares held by SMF under Section 13(d) of the Securities Exchange Act of 1934 (the \"Exchange Act\")."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Exchange Act, this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":432683,"source":{"system":"sec-edgar","filing":"0001213900-25-004766","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/919484/000121390025004766/ownership.xml","form_type":"4"}},{"id":1315952,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-01-03T21:40:08.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":5740,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":542111,"source":{"system":"sec-edgar","filing":"0001654954-25-000107","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425000107/section16.xml","form_type":"4"}},{"id":1315951,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-01-03T21:40:08.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":5382,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":536371,"source":{"system":"sec-edgar","filing":"0001654954-25-000107","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425000107/section16.xml","form_type":"4"}},{"id":1315948,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-01-03T21:27:12.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":7277,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":507020,"source":{"system":"sec-edgar","filing":"0001654954-25-000105","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425000105/section16.xml","form_type":"4"}},{"id":1315947,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2025-01-03T21:27:12.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":1300,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":499743,"source":{"system":"sec-edgar","filing":"0001654954-25-000105","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425000105/section16.xml","form_type":"4"}},{"id":1315950,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":84544,"kind":"person","name":"Masterson Nola E","position":1,"cik":"0001305231","reported_name":"Masterson Nola E","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2025-01-03T21:25:58.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":7528,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":130906,"source":{"system":"sec-edgar","filing":"0001654954-25-000103","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425000103/section16.xml","form_type":"4"}},{"id":1315949,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":84544,"kind":"person","name":"Masterson Nola E","position":1,"cik":"0001305231","reported_name":"Masterson Nola E","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2025-01-03T21:25:58.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":1354,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":123378,"source":{"system":"sec-edgar","filing":"0001654954-25-000103","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425000103/section16.xml","form_type":"4"}},{"id":1315946,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2025-01-03T21:24:51.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":8281,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":267772,"source":{"system":"sec-edgar","filing":"0001654954-25-000101","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425000101/section16.xml","form_type":"4"}},{"id":1315945,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2025-01-03T21:24:51.000Z","date":"2025-01-01","kind":"grant","planned":false,"acquired":true,"shares":1516,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":259491,"source":{"system":"sec-edgar","filing":"0001654954-25-000101","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495425000101/section16.xml","form_type":"4"}},{"id":1320084,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":2,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":3,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2024-12-31T11:47:29.000Z","date":"2024-12-26","kind":"purchase","planned":false,"acquired":true,"shares":7500,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are held by Strome Mezzanine Fund II, LP (\"SMF II). Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for the shares held by SME II. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934 (the \"Exchange Act\"), except to the extent of their pecuniary interest therein. This filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The reported securities are held by Strome Mezzanine Fund II, LP (\"SMF II). Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for the shares held by SME II. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934 (the \"Exchange Act\"), except to the extent of their pecuniary interest therein. This filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Strome Mezzanine Fund II, LP (\"SMF II). Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for the shares held by SME II. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934 (the \"Exchange Act\"), except to the extent of their pecuniary interest therein. This filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":44171,"derivative":{"exercise_price":20.19,"exercise_date":"2024-12-26","expiration_date":"2029-12-26","underlying":"Common Stock","underlying_shares":7500},"source":{"system":"sec-edgar","filing":"0001213900-24-113655","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/919484/000121390024113655/ownership.xml","form_type":"4"}},{"id":1320083,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":2,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":3,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2024-12-31T11:47:29.000Z","date":"2024-12-26","kind":"purchase","planned":false,"acquired":true,"shares":75000,"price":20.19,"value":1514250.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported securities are held by Strome Mezzanine Fund II, LP (\"SMF II). Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for the shares held by SME II. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934 (the \"Exchange Act\"), except to the extent of their pecuniary interest therein. This filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities are held by Strome Mezzanine Fund II, LP (\"SMF II). Strome Investment Management, LP is the general partner of SMF II. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark E. Strome is the President and CEO of Strome Group, Inc. Mr. Strome, Strome Investment Management, LP and Strome Group, Inc. (together, the \"Reporting Persons\") may be deemed to share voting and investment power for the shares held by SME II. The Reporting Persons disclaim beneficial ownership of the reported securities for purposes of Section 16 of the Securities Exchange Act of 1934 (the \"Exchange Act\"), except to the extent of their pecuniary interest therein. This filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":398683,"source":{"system":"sec-edgar","filing":"0001213900-24-113655","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/919484/000121390024113655/ownership.xml","form_type":"4"}},{"id":1385132,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant to Purchase Common Stock","published_at":"2024-10-17T23:33:33.000Z","date":"2024-10-16","kind":"purchase","planned":false,"acquired":true,"shares":313,"price":15.957,"value":4994.541,"ownership":{"direct":false,"nature":"By entity"},"balance_after":313,"derivative":{"exercise_price":15.957,"exercise_date":"2024-10-16","expiration_date":"2029-10-15","underlying":"Common Stock","underlying_shares":313},"source":{"system":"sec-edgar","filing":"0001641073-24-000004","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000164107324000004/primary_doc.xml","form_type":"4"}},{"id":1385131,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":63513,"kind":"person","name":"YALDOO LAITH L","position":1,"cik":"0001641073","reported_name":"YALDOO LAITH L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-10-17T23:33:33.000Z","date":"2024-10-16","kind":"purchase","planned":false,"acquired":true,"shares":3133,"price":15.957,"value":49993.281,"ownership":{"direct":false,"nature":"By entity"},"balance_after":533424,"source":{"system":"sec-edgar","filing":"0001641073-24-000004","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000164107324000004/primary_doc.xml","form_type":"4"}},{"id":1386130,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68620,"kind":"person","name":"PAYNE JOHN BERNARD","position":1,"cik":"0001582392","reported_name":"PAYNE JOHN BERNARD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock Warrant","published_at":"2024-10-16T20:07:29.000Z","date":"2024-10-16","kind":"purchase","planned":false,"acquired":true,"shares":634,"price":15.765,"value":9995.01,"ownership":{"direct":true},"balance_after":634,"derivative":{"exercise_price":15.765,"exercise_date":"2024-10-16","expiration_date":"2029-10-15","underlying":"Common Stock","underlying_shares":634},"source":{"system":"sec-edgar","filing":"0001654954-24-013034","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424013034/section16.xml","form_type":"4"}},{"id":1386129,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68620,"kind":"person","name":"PAYNE JOHN BERNARD","position":1,"cik":"0001582392","reported_name":"PAYNE JOHN BERNARD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-10-16T20:07:29.000Z","date":"2024-10-16","kind":"purchase","planned":false,"acquired":true,"shares":6343,"price":15.76,"value":99965.68,"ownership":{"direct":true},"balance_after":7909,"source":{"system":"sec-edgar","filing":"0001654954-24-013034","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424013034/section16.xml","form_type":"4"}},{"id":1424507,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock Purchase Warrants","published_at":"2024-08-23T20:09:53.000Z","date":"2024-08-22","kind":"purchase","planned":false,"acquired":true,"shares":1199,"price":8.34,"value":9999.66,"ownership":{"direct":true},"balance_after":1199,"derivative":{"exercise_price":8.34,"exercise_date":"2024-08-22","expiration_date":"2029-08-22","underlying":"Common Stock","underlying_shares":1199},"source":{"system":"sec-edgar","filing":"0001654954-24-011075","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424011075/section16.xml","form_type":"4"}},{"id":1424506,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2024-08-23T20:09:53.000Z","date":"2024-08-22","kind":"purchase","planned":false,"acquired":true,"shares":11990,"price":8.34,"value":99996.6,"ownership":{"direct":true},"balance_after":257975,"source":{"system":"sec-edgar","filing":"0001654954-24-011075","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424011075/section16.xml","form_type":"4"}},{"id":1424505,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock Purchase Warrants","published_at":"2024-08-23T20:05:51.000Z","date":"2024-08-22","kind":"purchase","planned":false,"acquired":true,"shares":3133,"price":8.34,"value":26129.22,"ownership":{"direct":true},"balance_after":3133,"derivative":{"exercise_price":8.34,"exercise_date":"2024-08-22","expiration_date":"2029-08-22","underlying":"Common Stock","underlying_shares":3133},"source":{"system":"sec-edgar","filing":"0001654954-24-011071","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424011071/section16.xml","form_type":"4"}},{"id":1424504,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-08-23T20:05:51.000Z","date":"2024-08-22","kind":"purchase","planned":false,"acquired":true,"shares":31336,"price":8.34,"value":261342.24,"ownership":{"direct":true},"balance_after":498443,"source":{"system":"sec-edgar","filing":"0001654954-24-011071","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424011071/section16.xml","form_type":"4"}},{"id":1446484,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock Purchase Warrant","published_at":"2024-07-30T20:58:49.000Z","date":"2024-07-26","kind":"purchase","planned":false,"acquired":true,"shares":208,"price":8.05,"value":1674.4,"ownership":{"direct":true},"balance_after":208,"derivative":{"exercise_price":8.05,"exercise_date":"2024-07-26","expiration_date":"2029-07-26","underlying":"Common Stock","underlying_shares":208},"source":{"system":"sec-edgar","filing":"0001654954-24-009647","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424009647/section16.xml","form_type":"4"}},{"id":1446483,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-07-30T20:58:49.000Z","date":"2024-07-26","kind":"purchase","planned":false,"acquired":true,"shares":2080,"price":8.05,"value":16744.0,"ownership":{"direct":true},"balance_after":467107,"source":{"system":"sec-edgar","filing":"0001654954-24-009647","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424009647/section16.xml","form_type":"4"}},{"id":1481069,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2024-06-13T21:37:59.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":6273,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":245985,"source":{"system":"sec-edgar","filing":"0001654954-24-007746","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007746/section16.xml","form_type":"4"}},{"id":1481068,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-13T21:37:18.000Z","date":"2024-06-12","kind":"purchase","planned":false,"acquired":true,"shares":3764,"price":7.97,"value":29999.08,"ownership":{"direct":true},"balance_after":465027,"source":{"system":"sec-edgar","filing":"0001654954-24-007745","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007745/section16.xml","form_type":"4"}},{"id":1481067,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-13T21:37:18.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":6273,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":461263,"source":{"system":"sec-edgar","filing":"0001654954-24-007745","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007745/section16.xml","form_type":"4"}},{"id":1481066,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":84544,"kind":"person","name":"Masterson Nola E","position":1,"cik":"0001305231","reported_name":"Masterson Nola E","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2024-06-13T21:36:07.000Z","date":"2024-06-11","kind":"grant","planned":false,"acquired":true,"shares":6273,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The reporting person's previous Form 4 filed on June 6, 2024 inadvertently included an additional 66 shares of common stock in the total securities beneficially owned, which has been corrected in this Form 4."}],"balance_after":122024,"source":{"system":"sec-edgar","filing":"0001654954-24-007744","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007744/section16.xml","form_type":"4"}},{"id":1488728,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:30:33.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3626,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 6/12/2023 and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2024 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service on each applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":16.74,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":3626},"source":{"system":"sec-edgar","filing":"0001654954-24-007464","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007464/section16.xml","form_type":"4"}},{"id":1488727,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:30:33.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":707,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":17.16,"expiration_date":"2032-12-15","underlying":"Common Stock","underlying_shares":707},"source":{"system":"sec-edgar","filing":"0001654954-24-007464","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007464/section16.xml","form_type":"4"}},{"id":1488726,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:30:33.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2632,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":21.66,"expiration_date":"2032-07-27","underlying":"Common Stock","underlying_shares":2632},"source":{"system":"sec-edgar","filing":"0001654954-24-007464","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007464/section16.xml","form_type":"4"}},{"id":1488725,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:30:33.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":7000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":33,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001654954-24-007464","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007464/section16.xml","form_type":"4"}},{"id":1488724,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:30:33.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1902,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":26.88,"expiration_date":"2031-10-11","underlying":"Common Stock","underlying_shares":1902},"source":{"system":"sec-edgar","filing":"0001654954-24-007464","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007464/section16.xml","form_type":"4"}},{"id":1488723,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-06T22:30:33.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":81544,"price":7.96,"value":649090.24,"ownership":{"direct":true},"balance_after":454990,"source":{"system":"sec-edgar","filing":"0001654954-24-007464","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007464/section16.xml","form_type":"4"}},{"id":1488722,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-06-06T22:30:33.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":36630,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 15,867 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 36,630 shares of restricted stock."}],"balance_after":373446,"source":{"system":"sec-edgar","filing":"0001654954-24-007464","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007464/section16.xml","form_type":"4"}},{"id":1488721,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":84544,"kind":"person","name":"Masterson Nola E","position":1,"cik":"0001305231","reported_name":"Masterson Nola E","relationship":{"director":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:28:46.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3626,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 6/12/2023 and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2024 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":16.74,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":3626},"source":{"system":"sec-edgar","filing":"0001654954-24-007463","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007463/section16.xml","form_type":"4"}},{"id":1488720,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":84544,"kind":"person","name":"Masterson Nola E","position":1,"cik":"0001305231","reported_name":"Masterson Nola E","relationship":{"director":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:28:46.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":707,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":17.16,"expiration_date":"2032-12-15","underlying":"Common Stock","underlying_shares":707},"source":{"system":"sec-edgar","filing":"0001654954-24-007463","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007463/section16.xml","form_type":"4"}},{"id":1488719,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":84544,"kind":"person","name":"Masterson Nola E","position":1,"cik":"0001305231","reported_name":"Masterson Nola E","relationship":{"director":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:28:46.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2632,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":21.66,"expiration_date":"2032-07-27","underlying":"Common Stock","underlying_shares":2632},"source":{"system":"sec-edgar","filing":"0001654954-24-007463","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007463/section16.xml","form_type":"4"}},{"id":1488718,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":84544,"kind":"person","name":"Masterson Nola E","position":1,"cik":"0001305231","reported_name":"Masterson Nola E","relationship":{"director":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:28:46.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":4333,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":33,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":4333},"source":{"system":"sec-edgar","filing":"0001654954-24-007463","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007463/section16.xml","form_type":"4"}},{"id":1488717,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":84544,"kind":"person","name":"Masterson Nola E","position":1,"cik":"0001305231","reported_name":"Masterson Nola E","relationship":{"director":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:28:46.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1902,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":26.88,"expiration_date":"2031-10-11","underlying":"Common Stock","underlying_shares":1902},"source":{"system":"sec-edgar","filing":"0001654954-24-007463","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007463/section16.xml","form_type":"4"}},{"id":1488716,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":84544,"kind":"person","name":"Masterson Nola E","position":1,"cik":"0001305231","reported_name":"Masterson Nola E","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-06T22:28:46.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":84941,"price":7.96,"value":676130.36,"ownership":{"direct":true},"balance_after":115817,"source":{"system":"sec-edgar","filing":"0001654954-24-007463","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007463/section16.xml","form_type":"4"}},{"id":1488715,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":84544,"kind":"person","name":"Masterson Nola E","position":1,"cik":"0001305231","reported_name":"Masterson Nola E","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-06T22:28:46.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":30010,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 13,200 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, 7/28/2022, 12/16/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 30,010 shares of restricted stock."}],"balance_after":30876,"source":{"system":"sec-edgar","filing":"0001654954-24-007463","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007463/section16.xml","form_type":"4"}},{"id":1488714,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:27:56.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3626,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 33,384 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 7/28/2022, 12/16/2022, 12/19/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 60,724 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 6/12/2023 and vested as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2024 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date."}],"balance_after":0,"derivative":{"exercise_price":16.74,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":3626},"source":{"system":"sec-edgar","filing":"0001654954-24-007462","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007462/section16.xml","form_type":"4"}},{"id":1488713,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:27:56.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23240,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 33,384 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 7/28/2022, 12/16/2022, 12/19/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 60,724 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":15.66,"expiration_date":"2032-12-18","underlying":"Common Stock","underlying_shares":23240},"source":{"system":"sec-edgar","filing":"0001654954-24-007462","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007462/section16.xml","form_type":"4"}},{"id":1488712,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:27:56.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":707,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 33,384 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 7/28/2022, 12/16/2022, 12/19/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 60,724 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":17.16,"expiration_date":"2032-12-15","underlying":"Common Stock","underlying_shares":707},"source":{"system":"sec-edgar","filing":"0001654954-24-007462","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007462/section16.xml","form_type":"4"}},{"id":1488711,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:27:56.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2632,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 33,384 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 7/28/2022, 12/16/2022, 12/19/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 60,724 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":21.66,"expiration_date":"2032-07-27","underlying":"Common Stock","underlying_shares":2632},"source":{"system":"sec-edgar","filing":"0001654954-24-007462","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007462/section16.xml","form_type":"4"}},{"id":1488710,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:27:56.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":3179,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 33,384 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 7/28/2022, 12/16/2022, 12/19/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 60,724 shares of restricted stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":26.88,"expiration_date":"2031-10-11","underlying":"Common Stock","underlying_shares":3179},"source":{"system":"sec-edgar","filing":"0001654954-24-007462","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007462/section16.xml","form_type":"4"}},{"id":1488709,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2024-06-06T22:27:56.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":95134,"price":7.96,"value":757266.64,"ownership":{"direct":true},"balance_after":239712,"source":{"system":"sec-edgar","filing":"0001654954-24-007462","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007462/section16.xml","form_type":"4"}},{"id":1488708,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2024-06-06T22:27:56.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":60724,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 33,384 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 7/28/2022, 12/16/2022, 12/19/2022, and 6/12/2023. In exchange for the canceled options, the Reporting Person received 60,724 shares of restricted stock."}],"balance_after":144578,"source":{"system":"sec-edgar","filing":"0001654954-24-007462","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007462/section16.xml","form_type":"4"}},{"id":1488707,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":90212,"kind":"person","name":"Marchiando Keith","position":1,"cik":"0001291432","reported_name":"Marchiando Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:26:45.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":444498,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 328,065 immediately upon grant acceptance, 13,551 on July 1, 2024, 13,442 on August 28, 2024, 62,447 on October 21, 2024, 13,551 on January 1, 2025, and 13,442 on August 28, 2025."}],"balance_after":444498,"derivative":{"exercise_price":7.96,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":444498},"source":{"system":"sec-edgar","filing":"0001654954-24-007461","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007461/section16.xml","form_type":"4"}},{"id":1488706,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":90212,"kind":"person","name":"Marchiando Keith","position":1,"cik":"0001291432","reported_name":"Marchiando Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:26:45.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":10333,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 8/29/2022 and vested as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant."}],"balance_after":0,"derivative":{"exercise_price":23.64,"expiration_date":"2032-08-28","underlying":"Common Stock","underlying_shares":10333},"source":{"system":"sec-edgar","filing":"0001654954-24-007461","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007461/section16.xml","form_type":"4"}},{"id":1488705,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":90212,"kind":"person","name":"Marchiando Keith","position":1,"cik":"0001291432","reported_name":"Marchiando Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:26:45.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":48000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The canceled option was issued pursuant to the 2021 Equity Incentive Plan on 10/21/2021 and vested as follows: 25% upon acceptance of the grant, and 25% on each of the next three calendar anniversaries of the grant."}],"balance_after":0,"derivative":{"exercise_price":33,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":48000},"source":{"system":"sec-edgar","filing":"0001654954-24-007461","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007461/section16.xml","form_type":"4"}},{"id":1488704,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":90212,"kind":"person","name":"Marchiando Keith","position":1,"cik":"0001291432","reported_name":"Marchiando Keith","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:26:45.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":27083,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 80 reverse stock split of the Issuer's stock in May 2021 and a 1 for 6 reverse stock split of the Issuer's stock in October 2023, as applicable."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 85,416 shares of the Issuer's common stock granted to the Reporting Person on 1/1/2021, 10/21/2021, and 8/29/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 444,498 shares, having an exercise price of $7.96."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled option was fully vested."}],"balance_after":0,"derivative":{"exercise_price":67.2,"expiration_date":"2030-12-31","underlying":"Common Stock","underlying_shares":27083},"source":{"system":"sec-edgar","filing":"0001654954-24-007461","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007461/section16.xml","form_type":"4"}},{"id":1488703,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68620,"kind":"person","name":"PAYNE JOHN BERNARD","position":1,"cik":"0001582392","reported_name":"PAYNE JOHN BERNARD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:25:29.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":50251,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was issued pursuant to the 2021 Equity Incentive Plan and all options vested immediately upon the date of acceptance of grant."}],"balance_after":50251,"derivative":{"exercise_price":7.96,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":50251},"source":{"system":"sec-edgar","filing":"0001654954-24-007460","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007460/section16.xml","form_type":"4"}},{"id":1488702,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68620,"kind":"person","name":"PAYNE JOHN BERNARD","position":1,"cik":"0001582392","reported_name":"PAYNE JOHN BERNARD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:25:29.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":167180,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 65,738 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, and 12/16/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 167,180 shares, having an exercise price of $7.96."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option was issued pursuant to the 2021 Equity Incentive Plan and all options vested immediately upon the date of acceptance of grant."}],"balance_after":167180,"derivative":{"exercise_price":7.96,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":167180},"source":{"system":"sec-edgar","filing":"0001654954-24-007460","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007460/section16.xml","form_type":"4"}},{"id":1488701,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68620,"kind":"person","name":"PAYNE JOHN BERNARD","position":1,"cik":"0001582392","reported_name":"PAYNE JOHN BERNARD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:25:29.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31836,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 65,738 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, and 12/16/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 167,180 shares, having an exercise price of $7.96."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":17.16,"expiration_date":"2032-12-15","underlying":"Common Stock","underlying_shares":31836},"source":{"system":"sec-edgar","filing":"0001654954-24-007460","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007460/section16.xml","form_type":"4"}},{"id":1488700,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68620,"kind":"person","name":"PAYNE JOHN BERNARD","position":1,"cik":"0001582392","reported_name":"PAYNE JOHN BERNARD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:25:29.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 65,738 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, and 12/16/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 167,180 shares, having an exercise price of $7.96."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":33,"expiration_date":"2031-10-20","underlying":"Common Stock","underlying_shares":32000},"source":{"system":"sec-edgar","filing":"0001654954-24-007460","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007460/section16.xml","form_type":"4"}},{"id":1488699,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68620,"kind":"person","name":"PAYNE JOHN BERNARD","position":1,"cik":"0001582392","reported_name":"PAYNE JOHN BERNARD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2024-06-06T22:25:29.000Z","date":"2024-06-05","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1902,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"shares","element":"transactionShares","label":"F1","text":"The share amount and exercise price have been adjusted from the amount reported on a previous Form 4 to reflect a 1 for 6 reverse stock split of the Issuer's stock in October 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The Issuer canceled options for an aggregate 65,738 shares of the Issuer's common stock granted to the Reporting Person on 10/12/2021, 10/21/2021, and 12/16/2022. In exchange for the canceled options, the Reporting Person received a replacement option, for 167,180 shares, having an exercise price of $7.96."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The canceled options were fully vested."}],"balance_after":0,"derivative":{"exercise_price":26.88,"expiration_date":"2031-10-11","underlying":"Common Stock","underlying_shares":1902},"source":{"system":"sec-edgar","filing":"0001654954-24-007460","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007460/section16.xml","form_type":"4"}},{"id":1493130,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2024-06-04T21:16:40.000Z","date":"2024-05-31","kind":"grant","planned":false,"acquired":true,"shares":37688,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":83854,"source":{"system":"sec-edgar","filing":"0001654954-24-007348","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424007348/section16.xml","form_type":"4"}},{"id":1688631,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true,"officer":false,"ten_percent_owner":false}}],"security":"Common Stock","published_at":"2024-01-04T21:05:16.000Z","date":"2024-01-02","kind":"purchase","planned":false,"acquired":true,"shares":41666,"price":1.2,"value":49999.2,"ownership":{"direct":true},"balance_after":68666,"source":{"system":"sec-edgar","filing":"0001654954-24-000193","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424000193/section16.xml","form_type":"4"}},{"id":1696874,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2024-01-02T21:12:09.000Z","date":"2023-12-29","kind":"purchase","planned":false,"acquired":true,"shares":157692,"price":1.3,"value":204999.6,"ownership":{"direct":true},"balance_after":336816,"source":{"system":"sec-edgar","filing":"0001654954-24-000086","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495424000086/section16.xml","form_type":"4"}},{"id":1711212,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true,"officer":false,"ten_percent_owner":true}}],"security":"Common Stock","published_at":"2023-12-14T20:45:36.000Z","date":"2023-12-13","kind":"purchase","planned":false,"acquired":true,"shares":45000,"price":1,"value":45000.0,"ownership":{"direct":true},"balance_after":179124,"source":{"system":"sec-edgar","filing":"0001654954-23-015555","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423015555/section16.xml","form_type":"4"}},{"id":1754025,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108723,"kind":"organization","name":"STROME MEZZANINE FUND, LP","position":2,"cik":"0001713153","reported_name":"STROME MEZZANINE FUND, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108724,"kind":"organization","name":"Strome Alpha Fund L P","position":3,"cik":"0001324539","reported_name":"Strome Alpha Fund L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":4,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":5,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2023-10-30T21:01:28.000Z","date":"2022-11-20","kind":"other","planned":false,"acquired":false,"shares":4166,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Expiration of long derivative position (warrant) without value received."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This filing is made on behalf of Strome Mezzanine Fund, L.P (\"Strome Mezzanine\"), Strome Alpha Fund LP (\"Strome Alpha\"), Strome Investment Management, LP, Strome Group, Inc., and Mark Strome (together, the \"Reporting Persons\"). Strome Investment Management, LP is the general partner of Strome Mezzanine. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark Strome is the President and CEO of Strome Group, Inc. Strome Investment Management, LP, Strome Group, Inc., and Mark Strome may be deemed to share voting and investment power for the shares held by Strome Mezzanine and Strome Alpha."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2017-11-20","expiration_date":"2022-11-20","underlying":"Common Stock","underlying_shares":4166},"source":{"system":"sec-edgar","filing":"0001793373-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/919484/000179337323000005/primary_doc.xml","form_type":"4"}},{"id":1754024,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108723,"kind":"organization","name":"STROME MEZZANINE FUND, LP","position":2,"cik":"0001713153","reported_name":"STROME MEZZANINE FUND, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108724,"kind":"organization","name":"Strome Alpha Fund L P","position":3,"cik":"0001324539","reported_name":"Strome Alpha Fund L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":4,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":5,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2023-10-30T21:01:28.000Z","date":"2022-11-20","kind":"other","planned":false,"acquired":false,"shares":104166,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Expiration of long derivative position (warrant) without value received."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This filing is made on behalf of Strome Mezzanine Fund, L.P (\"Strome Mezzanine\"), Strome Alpha Fund LP (\"Strome Alpha\"), Strome Investment Management, LP, Strome Group, Inc., and Mark Strome (together, the \"Reporting Persons\"). Strome Investment Management, LP is the general partner of Strome Mezzanine. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark Strome is the President and CEO of Strome Group, Inc. Strome Investment Management, LP, Strome Group, Inc., and Mark Strome may be deemed to share voting and investment power for the shares held by Strome Mezzanine and Strome Alpha."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2017-11-20","expiration_date":"2022-11-20","underlying":"Common Stock","underlying_shares":104166},"source":{"system":"sec-edgar","filing":"0001793373-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/919484/000179337323000005/primary_doc.xml","form_type":"4"}},{"id":1754023,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108723,"kind":"organization","name":"STROME MEZZANINE FUND, LP","position":2,"cik":"0001713153","reported_name":"STROME MEZZANINE FUND, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108724,"kind":"organization","name":"Strome Alpha Fund L P","position":3,"cik":"0001324539","reported_name":"Strome Alpha Fund L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":4,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":5,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2023-10-30T21:01:28.000Z","date":"2022-11-20","kind":"other","planned":false,"acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Expiration of long derivative position (warrant) without value received."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This filing is made on behalf of Strome Mezzanine Fund, L.P (\"Strome Mezzanine\"), Strome Alpha Fund LP (\"Strome Alpha\"), Strome Investment Management, LP, Strome Group, Inc., and Mark Strome (together, the \"Reporting Persons\"). Strome Investment Management, LP is the general partner of Strome Mezzanine. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark Strome is the President and CEO of Strome Group, Inc. Strome Investment Management, LP, Strome Group, Inc., and Mark Strome may be deemed to share voting and investment power for the shares held by Strome Mezzanine and Strome Alpha."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2017-11-20","expiration_date":"2022-11-20","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001793373-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/919484/000179337323000005/primary_doc.xml","form_type":"4"}},{"id":1754022,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108723,"kind":"organization","name":"STROME MEZZANINE FUND, LP","position":2,"cik":"0001713153","reported_name":"STROME MEZZANINE FUND, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108724,"kind":"organization","name":"Strome Alpha Fund L P","position":3,"cik":"0001324539","reported_name":"Strome Alpha Fund L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":4,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":5,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2023-10-30T21:01:28.000Z","date":"2022-11-20","kind":"other","planned":false,"acquired":false,"shares":8333,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Expiration of long derivative position (warrant) without value received."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This filing is made on behalf of Strome Mezzanine Fund, L.P (\"Strome Mezzanine\"), Strome Alpha Fund LP (\"Strome Alpha\"), Strome Investment Management, LP, Strome Group, Inc., and Mark Strome (together, the \"Reporting Persons\"). Strome Investment Management, LP is the general partner of Strome Mezzanine. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark Strome is the President and CEO of Strome Group, Inc. Strome Investment Management, LP, Strome Group, Inc., and Mark Strome may be deemed to share voting and investment power for the shares held by Strome Mezzanine and Strome Alpha."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2017-11-20","expiration_date":"2022-11-20","underlying":"Common Stock","underlying_shares":8333},"source":{"system":"sec-edgar","filing":"0001793373-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/919484/000179337323000005/primary_doc.xml","form_type":"4"}},{"id":1754021,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108723,"kind":"organization","name":"STROME MEZZANINE FUND, LP","position":2,"cik":"0001713153","reported_name":"STROME MEZZANINE FUND, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108724,"kind":"organization","name":"Strome Alpha Fund L P","position":3,"cik":"0001324539","reported_name":"Strome Alpha Fund L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":4,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":5,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2023-10-30T21:01:28.000Z","date":"2022-11-20","kind":"other","planned":false,"acquired":false,"shares":208333,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Expiration of long derivative position (warrant) without value received."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This filing is made on behalf of Strome Mezzanine Fund, L.P (\"Strome Mezzanine\"), Strome Alpha Fund LP (\"Strome Alpha\"), Strome Investment Management, LP, Strome Group, Inc., and Mark Strome (together, the \"Reporting Persons\"). Strome Investment Management, LP is the general partner of Strome Mezzanine. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark Strome is the President and CEO of Strome Group, Inc. Strome Investment Management, LP, Strome Group, Inc., and Mark Strome may be deemed to share voting and investment power for the shares held by Strome Mezzanine and Strome Alpha."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2017-11-20","expiration_date":"2022-11-20","underlying":"Common Stock","underlying_shares":208333},"source":{"system":"sec-edgar","filing":"0001793373-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/919484/000179337323000005/primary_doc.xml","form_type":"4"}},{"id":1754020,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108723,"kind":"organization","name":"STROME MEZZANINE FUND, LP","position":2,"cik":"0001713153","reported_name":"STROME MEZZANINE FUND, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108724,"kind":"organization","name":"Strome Alpha Fund L P","position":3,"cik":"0001324539","reported_name":"Strome Alpha Fund L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":4,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":5,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2023-10-30T21:01:28.000Z","date":"2022-09-25","kind":"other","planned":false,"acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Expiration of long derivative position (warrant) without value received."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This filing is made on behalf of Strome Mezzanine Fund, L.P (\"Strome Mezzanine\"), Strome Alpha Fund LP (\"Strome Alpha\"), Strome Investment Management, LP, Strome Group, Inc., and Mark Strome (together, the \"Reporting Persons\"). Strome Investment Management, LP is the general partner of Strome Mezzanine. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark Strome is the President and CEO of Strome Group, Inc. Strome Investment Management, LP, Strome Group, Inc., and Mark Strome may be deemed to share voting and investment power for the shares held by Strome Mezzanine and Strome Alpha."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2017-09-25","expiration_date":"2022-09-25","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001793373-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/919484/000179337323000005/primary_doc.xml","form_type":"4"}},{"id":1754019,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108723,"kind":"organization","name":"STROME MEZZANINE FUND, LP","position":2,"cik":"0001713153","reported_name":"STROME MEZZANINE FUND, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108724,"kind":"organization","name":"Strome Alpha Fund L P","position":3,"cik":"0001324539","reported_name":"Strome Alpha Fund L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":4,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":5,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2023-10-30T21:01:28.000Z","date":"2022-07-24","kind":"other","planned":false,"acquired":false,"shares":3125,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Expiration of long derivative position (warrant) without value received."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This filing is made on behalf of Strome Mezzanine Fund, L.P (\"Strome Mezzanine\"), Strome Alpha Fund LP (\"Strome Alpha\"), Strome Investment Management, LP, Strome Group, Inc., and Mark Strome (together, the \"Reporting Persons\"). Strome Investment Management, LP is the general partner of Strome Mezzanine. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark Strome is the President and CEO of Strome Group, Inc. Strome Investment Management, LP, Strome Group, Inc., and Mark Strome may be deemed to share voting and investment power for the shares held by Strome Mezzanine and Strome Alpha."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":0,"derivative":{"exercise_price":8,"exercise_date":"2017-07-24","expiration_date":"2022-07-24","underlying":"Common Stock","underlying_shares":3125},"source":{"system":"sec-edgar","filing":"0001793373-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/919484/000179337323000005/primary_doc.xml","form_type":"4"}},{"id":1754018,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108723,"kind":"organization","name":"STROME MEZZANINE FUND, LP","position":2,"cik":"0001713153","reported_name":"STROME MEZZANINE FUND, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108724,"kind":"organization","name":"Strome Alpha Fund L P","position":3,"cik":"0001324539","reported_name":"Strome Alpha Fund L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":4,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":5,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Convertible Debt","published_at":"2023-10-30T21:01:28.000Z","date":"2021-06-02","kind":"exercise","planned":false,"acquired":false,"shares":2191187,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The convertible debt was convertible at any time prior to, and did not expire until, the repayment or conversion of the convertible debt in full."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The convertible debt was convertible at any time prior to, and did not expire until, the repayment or conversion of the convertible debt in full."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This filing is made on behalf of Strome Mezzanine Fund, L.P (\"Strome Mezzanine\"), Strome Alpha Fund LP (\"Strome Alpha\"), Strome Investment Management, LP, Strome Group, Inc., and Mark Strome (together, the \"Reporting Persons\"). Strome Investment Management, LP is the general partner of Strome Mezzanine. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark Strome is the President and CEO of Strome Group, Inc. Strome Investment Management, LP, Strome Group, Inc., and Mark Strome may be deemed to share voting and investment power for the shares held by Strome Mezzanine and Strome Alpha."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":0,"derivative":{"exercise_price":8,"underlying":"Common Stock","underlying_shares":326286},"source":{"system":"sec-edgar","filing":"0001793373-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/919484/000179337323000005/primary_doc.xml","form_type":"4"}},{"id":1754017,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108723,"kind":"organization","name":"STROME MEZZANINE FUND, LP","position":2,"cik":"0001713153","reported_name":"STROME MEZZANINE FUND, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108724,"kind":"organization","name":"Strome Alpha Fund L P","position":3,"cik":"0001324539","reported_name":"Strome Alpha Fund L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":4,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":5,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrant","published_at":"2023-10-30T21:01:28.000Z","date":"2021-06-02","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":0.01,"value":400.0,"ownership":{"direct":false,"nature":"By trust"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":40000,"derivative":{"exercise_price":5.5,"exercise_date":"2021-06-02","expiration_date":"2026-06-02","underlying":"Common Stock","underlying_shares":40000},"source":{"system":"sec-edgar","filing":"0001793373-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/919484/000179337323000005/primary_doc.xml","form_type":"4"}},{"id":1754016,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108723,"kind":"organization","name":"STROME MEZZANINE FUND, LP","position":2,"cik":"0001713153","reported_name":"STROME MEZZANINE FUND, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108724,"kind":"organization","name":"Strome Alpha Fund L P","position":3,"cik":"0001324539","reported_name":"Strome Alpha Fund L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":4,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":5,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-30T21:01:28.000Z","date":"2021-06-02","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":4.99,"value":199600.0,"ownership":{"direct":false,"nature":"By trust"},"balance_after":203601,"source":{"system":"sec-edgar","filing":"0001793373-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/919484/000179337323000005/primary_doc.xml","form_type":"4"}},{"id":1754015,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":51407,"kind":"person","name":"STROME MARK E","position":1,"cik":"0000919484","reported_name":"STROME MARK E","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108723,"kind":"organization","name":"STROME MEZZANINE FUND, LP","position":2,"cik":"0001713153","reported_name":"STROME MEZZANINE FUND, LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108724,"kind":"organization","name":"Strome Alpha Fund L P","position":3,"cik":"0001324539","reported_name":"Strome Alpha Fund L P","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51408,"kind":"organization","name":"STROME INVESTMENT MANAGEMENT LP","position":4,"cik":"0000936711","reported_name":"STROME INVESTMENT MANAGEMENT LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":51409,"kind":"organization","name":"STROME GROUP, INC.","position":5,"cik":"0001724136","reported_name":"STROME GROUP, INC.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-10-30T21:01:28.000Z","date":"2021-06-02","kind":"exercise","planned":false,"acquired":true,"shares":326286,"price":8,"value":2610288.0,"ownership":{"direct":false,"nature":"By entity"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction resulted from the conversion of convertible debt into shares of common stock at $8.00."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"This filing is made on behalf of Strome Mezzanine Fund, L.P (\"Strome Mezzanine\"), Strome Alpha Fund LP (\"Strome Alpha\"), Strome Investment Management, LP, Strome Group, Inc., and Mark Strome (together, the \"Reporting Persons\"). Strome Investment Management, LP is the general partner of Strome Mezzanine. Strome Group, Inc. is the general partner of Strome Investment Management, LP. Mark Strome is the President and CEO of Strome Group, Inc. Strome Investment Management, LP, Strome Group, Inc., and Mark Strome may be deemed to share voting and investment power for the shares held by Strome Mezzanine and Strome Alpha."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Pursuant to Rule 16a-1(a)(4) of the Securities Exchange Act of 1934 (the \"Exchange Act\"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owner of any equity securities reported herein."}],"balance_after":326286,"source":{"system":"sec-edgar","filing":"0001793373-23-000005","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/919484/000179337323000005/primary_doc.xml","form_type":"4"}},{"id":1856273,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68621,"kind":"person","name":"Cornell Alison A","position":1,"cik":"0001549395","reported_name":"Cornell Alison A","relationship":{"director":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2023-06-14T21:05:42.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":21756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2024 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date."}],"balance_after":21756,"derivative":{"exercise_price":2.79,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":21756},"source":{"system":"sec-edgar","filing":"0001654954-23-008024","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423008024/section16.xml","form_type":"4"}},{"id":1856272,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2023-06-14T21:05:33.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":21756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2024 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date."}],"balance_after":21756,"derivative":{"exercise_price":2.79,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":21756},"source":{"system":"sec-edgar","filing":"0001654954-23-008023","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423008023/section16.xml","form_type":"4"}},{"id":1856271,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":84544,"kind":"person","name":"Masterson Nola E","position":1,"cik":"0001305231","reported_name":"Masterson Nola E","relationship":{"director":true}}],"security":"Nonstatutory Stock Option to Purchase Common Stock","published_at":"2023-06-14T21:05:29.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":21756,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the 2021 Equity Incentive Plan and vests as follows: 25% on the first three 3-month anniversaries of the grant, and 25% on the day prior to the Company's 2024 Annual Meeting of Stockholders, subject to the reporting person's continuous service on each applicable vesting date."}],"balance_after":21756,"derivative":{"exercise_price":2.79,"expiration_date":"2033-06-11","underlying":"Common Stock","underlying_shares":21756},"source":{"system":"sec-edgar","filing":"0001654954-23-008022","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423008022/section16.xml","form_type":"4"}},{"id":1925517,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68620,"kind":"person","name":"PAYNE JOHN BERNARD","position":1,"cik":"0001582392","reported_name":"PAYNE JOHN BERNARD","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock Purchase Warrant","published_at":"2023-04-05T21:10:44.000Z","date":"2023-04-03","kind":"purchase","planned":false,"acquired":true,"shares":390000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The warrant was issued in connection with a private placement and purchase of a promissory note by Mr. Payne in the principal amount of $1,000,000."}],"balance_after":390000,"derivative":{"exercise_price":2.91,"exercise_date":"2023-04-03","expiration_date":"2026-04-02","underlying":"Common Stock","underlying_shares":390000},"source":{"system":"sec-edgar","filing":"0001654954-23-004461","document":"section16.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423004461/section16.xml","form_type":"4"}},{"id":2017222,"issuer":{"id":9611,"kind":"organization","name":"Zivo Bioscience, Inc."},"owners":[{"id":68727,"kind":"person","name":"Maggiore Christopher D.","position":1,"cik":"0001436075","reported_name":"Maggiore Christopher D.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-02-14T13:33:15.000Z","date":"2022-09-14","kind":"purchase","acquired":true,"shares":2000,"price":3.5507,"value":7101.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The reported price in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.435 to $3.93 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."}],"balance_after":723282,"source":{"system":"sec-edgar","filing":"0001654954-23-001647","document":"section16.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1101026/000165495423001647/section16.xml","form_type":"4/A","original_submission_date":"2022-09-19"}}],"next_cursor":"2023-02-14T13:33:15.000000Z,2017222"}